Qiagen (QGEN) Investor presentation summary

Strategic focus and market positioning

• Targets solid profitable growth with a focus on innovation, efficiency, and disciplined capital allocation.

• Operates in life sciences and molecular diagnostics, addressing a $13-14 bn market with 4-6% CAGR through 2028.

• Over 85% of revenues are highly recurring, with a diversified global presence and balanced product portfolio.

• Leadership team has been reinvigorated, with significant new appointments since 2020.

• ESG initiatives include a net zero carbon target by 2050 and top-tier ESG ratings.

Financial performance and outlook

• Q3 2024 net sales grew 6% CER to $502 million, with adjusted EPS up 16% CER to $0.57.

• Adjusted operating income margin rose to 29.6%, up 3 ppt from Q3 2023, reflecting efficiency gains.

• Free cash flow increased 56% to $139 million in Q3 2024; 9M 2024 free cash flow up 73% to $364 million.

• FY 2024 outlook reaffirmed: net sales >$1.985 bn CER, adjusted EPS >$2.19 CER, and operating margin ≥28.5%.

• Strong balance sheet with $1.48 bn liquidity and a leverage ratio of 0.6x as of September 2024.

Growth drivers and product innovation

• Key growth pillars: QIAcuity dPCR, QIAstat-Dx, QuantiFERON, and Digital Insights, each targeting significant market expansion by 2028.

• QIAcuity dPCR targets >$250 mn net sales by 2028, with >2,000 placements and >2,300 validated assays.

• QIAstat-Dx achieved >4,000 placements, 40% CER sales growth in Q3 2024, and aims for ≥$200 mn net sales by 2028.

• QuantiFERON leads latent TB testing, with $408 mn 2023 sales (+70% vs. 2019) and a ≥$600 mn 2028 target.

• Digital Insights (QDI) is #1 in bioinformatics, with $100 mn 2023 sales and a ≥$200 mn 2028 target.